Dr. Timos Papagatsias的动态

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Roche buys out CAR-T partner Poseida for $1B upfront: Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving Poseida ... #lucidquest #genetherapy #celltherapy

?????????? ???????? ?????? ??????-?? ?????????????? ?????????????? ?????? $???? ?????????????? Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. https://lnkd.in/dS9-y2vG

After inking an up to $6 billion partnership with Poseida Therapeutics in 2022, Roche is now paying $1 billion upfront to acquire all of its off-the-shelf cell therapy and genomic medicines partner. The Swiss pharma giant is gaining a pipeline of oncology, autoimmune and neurology treatment candidates. “We do really think this is only the beginning. And when you think about it this way, then the answer becomes almost a foregone conclusion that there is so much complementarity, there is so much potential, we should become one,” Aviv Regev, head of research and early development at Genentech, said in an interview with Endpoints News. #roche #poseida #sandiegobiotech #biotech #pharma #biotechacquisition #allogeneic #offtheshelf #celltherapy #genomicmedicines #multiplemyeloma #hemophiliaa #hereditaryangioedema

?? Live from the 19th BioPharma Drug Discovery Nexus Conference! Join Lars Nieba CEO at Engimmune Therapeutics, as he unveils groundbreaking insights on coupling protein engineering with AI to develop multi-specific, soluble TCR-based cell engagers for oncology and auto-immune diseases. Don't miss this enlightening session! #BioPharma #DrugDiscovery #Innovation #NexusConference #Switzerland #Proteinengineering #AI #Cell #TCR #ImmuneDiseases #ProcurementDirect #LiveUpdate #ConferenceLive #DiscoveryConference #EuropeEvent

The beauty of oligonucleotide and RNAi therapies are the fact that the treatments are not permanent, but exhibit durable effectiveness as compared to small molecule therapies. In the coming years, we will begin to see additional therapies targeting CNS diseases, weight loss, and other opportunities. As such, many feel that we are entering a "Golden Age" for companies like Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Silence Therapeutics plc, and others. Do you have any thoughts about the growing field of gene silencing therapies? $IONS $ARWR $ALNY $SLN #oligonucleotides #rnai #genesilencing #clinicaltrials #innovation

Here are some of the latest biopharma news stories 1 2 3 ?: - Bristol Myers Squibb’s ongoing portfolio reprioritization puts Eisai in charge of developing and marketing farletuzumab ecteribulin. - The U.S. Supreme Court's overturning of the long-standing Chevron doctrine might limit the FDA's regulatory authority. - Samsung Bioepis' Pyzchiva will be marketed in the U.S. by Sandoz. - Daiichi Sankyo wins a $47 million arbitration award against Seagen for legal fees and other costs, plus interest. - Gilead Sciences' Trodelvy faces clinical obstacles in 2024 in bladder and lung cancer despite analysts' optimism about its oncology prospects. - In 2023, the FDA authorized 55 new medications and 34 cell and gene therapies. Ref 1-https://lnkd.in/gZYKFhs6 Ref 2-https://lnkd.in/gQc9nbYQ Ref 3-https://lnkd.in/g7XdPHEf Ref 4-https://lnkd.in/gNCP2AwC

Did you miss it? Last month, we introduced our groundbreaking chemical modification search tool! If you are working in oligonucleotide therapeutics, and want to enhance your innovation capabilities, take a look at the link below and explore what this revolutionary tool can do for you! #oligonucleotide #RNA #chemicalmodification #innovation

Globally, over 4,000 #CGT therapies are currently in development, with 31 #gene therapies and 68 #non-genetically modified cell therapies already clinically approved. These advancements offer immense hope for patients but also present complex challenges for sponsors. Navigating these challenges effectively is crucial for achieving regulatory approval and clinical success. Achieving success in #cell and #gene therapy development requires not only innovation but also a comprehensive strategy that addresses clinical, operational, and regulatory challenges. At Tigermed, we are committed to supporting our clients through this complex landscape to bring life-changing therapies to patients worldwide. Read on to learn the latest on #CGT drug development, future trends, and how to stand out from the competition: https://lnkd.in/gCxrr2DW

Focus on Drug Approvals. Last week the FDA approved Revumenib (SNDX-5613, Syndax Pharmaceuticals) a menin inhibitor for relapsed or refractory acute leukemia with lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. For more info see: https://lnkd.in/gP8gK7Qa and: https://syndax.com Focus Biomolecules can supply SNDX-5613 for research applications. Contact us for more info. https://lnkd.in/dG8wyUz6 #Drugdiscovery #cancerresearch #smallmolecules #pharmacology

Genenta Science has?expanded?its partnership with AGC Biologics, amending their Development and Master Services Agreement to secure an exclusive GMP suite at AGC Biologics’ Cell and Gene Center of Excellence in Milan, Italy. Genenta Science (Nasdaq: GNTA) #GenentaScience #AGCBiologics #partnership #agreement #GMPsuite #pharmanews #pharmamanufacturing https://lnkd.in/gUVX3-v8